In focus.

Aratana Therapeutics, Trevena and Sangamo Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Endo International slipped 5% ahead of market's open Friday.

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Also on the move were Global Blood Therapeutics, Valeant and Kite Pharma, among others.

Also falling was Global Blood Therapeutics.

Gilead (finally!) has acquired something from Sarepta, even if it is quite small.

Trevena intends to submit the new painkiller, known as oliceridine, for marketing approval with the U.S. Food and Drug Administration in the fourth quarter, the company said.

Trevena's oliceridine seeks to provide the pain relief of morphine with less side effects.

U.S. inflation slowed notably last month, data from the Bureau of Labor Statistics indicated Wednesday, setting the possibility of a pause in Fed rate hikes.

The theme park giant has been trying to make changes and that has caused some issues for its guests.

The pizza giant goes someplace pizza fans may not want to follow but Domino's, Pizza Hit, and Little Caesars don't sell this.